Skip to main content

Table 1 Clinicopathological and treatment-related characteristics of the patients

From: Axitinib as a third or further line of treatment in renal cancer: a single institution experience

Characterstics

Median

Range

Age

55,4

30,2-73,5

 

N

%

Sex

 Male

11

50

 Female

11

50

Histology

 ccRCC

17

77,3

 non-ccRCC

5

22,7

Nephrectomy

 Yes

22

100

 No

0

0

Fuhrman grade

  < 3

6

27,3

  ≥ 3

13

59,1

 NA

3

13,6

Heng prognostic group at 1st line

 Good

6

27,3

 Intermediate

13

59,1

 Poor

1

4,5

 NA

2

9,1

Heng prognostic group at axitinib line

 Good

0

0

 Intermediate

9

40,9

 Poor

11

50

 NA

2

9,1

Axitinb line of treatment

 3

12

54,5

 4

4

18,2

  > 4

6

27,3

Previous treatments

 TKI only

1

4,5

 TKI/IO

2

9,1

 TKI/mTOR inhibitor

19

85,3

No of previous TKIs received

  < 2

11

50

  ≥ 2

11

50

No of metastatic sites at axitinib treatment

 solitary

4

18,2

 multiple

18

81,8

Sites of metastases at axitinib treatment

 lymph nodes

12

54,5

 lung

19

85,3

 liver

9

40,9

 bone

5

22,7

 local relapse

8

36,4